Pulmonx to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will participate in two investor conferences in New York. Management will hold a fireside chat at the Stifel Healthcare Conference on November 16, 2022, at 8:00 AM ET, with a live webcast available on their website. Additionally, they will engage in investor meetings at the Canaccord Genuity MedTech Forum on November 17, 2022. The company’s Zephyr Valve, used for treating emphysema/COPD, has gained FDA approval and is available in over 25 countries.

REDWOOD CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York.

Pulmonx management is scheduled to participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 16, 2022, at 8:00AM ET. Interested parties may access a live and archived webcast of the event on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

Pulmonx management will also be participating in investor meetings at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 17, 2022.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

When is Pulmonx participating in the Stifel Healthcare Conference?

Pulmonx will participate in the Stifel Healthcare Conference on November 16, 2022, at 8:00 AM ET.

How can I access the Pulmonx fireside chat?

The fireside chat can be accessed live and in archived format on the 'Investors' section of the Pulmonx website.

What other event will Pulmonx attend in November 2022?

Pulmonx will also participate in investor meetings at the Canaccord Genuity MedTech Forum on November 17, 2022.

What is the significance of the Zephyr Valve for Pulmonx?

The Zephyr Valve is crucial for Pulmonx, as it is FDA-approved and has been used to treat more than 25,000 patients with severe emphysema/COPD.

How many countries is the Zephyr Valve available in?

The Zephyr Valve is commercially available in over 25 countries.